Exciting Leadership Transitions at ImmunoTek

Itek Leadership Chg Website50 01

ImmunoTek is proud to announce significant leadership changes that became effective May 1 as part of our ongoing commitment to excellence and innovation. These moves enhance our governance and operational efficiency, ensuring continued leadership in the biopharmaceutical industry.

  • Jerome Parnell III, the visionary founder of ImmunoTek, will transition from CEO to Vice Chairman of the Board. Jerome will shift from his day-to-day operational responsibilities to focus on oversight and governance. With his leadership and deep industry knowledge, Jerome will continue to guide ImmunoTek, ensuring we remain pioneers in our field.
  • Marvin Dyke, previously President, will ascend to the role of CEO. Marvin is celebrated for his decisive leadership and profound understanding of our operations. As CEO, he will oversee all strategic and operational responsibilities, ensuring alignment with our long-term goals and board expectations.

We are deeply grateful to Jerome for his transformative leadership as CEO, under which ImmunoTek has grown and thrived. Congratulations to Marvin on his new role, where his leadership will continue to fuel innovation and growth, keeping ImmunoTek at the forefront of our industry.

Join us in celebrating these pivotal changes as we advance and set standards in our field.